Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients : new insights into vitamin D receptor activation by J. Bover & M. Cozzolino
Mineral and bone disorders in chronic kidney disease
and end-stage renal disease patients: new insights
into vitamin D receptor activation
Jordi Bover1 and Mario Cozzolino2
1Department of Nephrology, Fundacio´ Puigvert, Hospital de la Santa Creu i Sant Pau, Universitat Auto`noma de Barcelona, Catalonia,
Spain and 2Renal Division, Department of Medicine, Surgery, and Dentistry, San Paolo Hospital, University of Milan, Milan, Italy
Progressive loss of kidney function leads to reduced
production of calcitriol (1,25-dihydroxyvitamin D; active
vitamin D) and an imbalance in serum calcium (Ca) and
phosphorus (P) levels, which are associated with progression
of renal failure as well as increased rates of cardiovascular
(CV) events and mortality. In addition, multifactorial
hypocalcemia and resistance to parathyroid hormone (PTH)
can lead to prolonged and excessive synthesis and secretion
of PTH, eventually leading to development of secondary
hyperparathyroidism and renal osteodystrophy. These
changes associated with chronic kidney disease (CKD),
extending beyond bone and related biochemical
abnormalities, have prompted the development of the term
CKD–mineral and bone disorder to describe its systemic
nature. Excessive P loading, among other factors, will
promote vascular calcification (VC), and PTH production
will affect bone remodeling. Although administration of
calcitriol increases serum Ca levels and decreases PTH, it is
also associated with elevated CaP product. Therefore,
compounds that selectively activate vitamin D receptors
(VDR activators), potentially reducing Ca–P toxicity and
distinctly affecting pathogenic mechanisms of VC, might
enhance CV and renal protection, increase the vitamin D
therapeutic window, and thus provide a significant clinical
benefit. Moreover, selective VDR activators have been
associated with improvement in survival, at least among
dialysis patients. Thus, selective VDR activators should be
considered a novel and interesting approach to enhance the
standard of care
in CKD patients.
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Progressive loss of kidney function in chronic kidney disease
(CKD) leads to reduced production of 1-a-(OH)2-D3 (1,25-
dihydroxyvitamin D; calcitriol) and abnormal mineral
homeostasis reflected mainly by an imbalance in both serum
calcium (Ca) and phosphorus (P) levels, as well as increasing
levels of parathyroid hormone (PTH).1–3 Prevention of
evolving secondary hyperparathyroidism (SHPT) and renal
osteodystrophy was classically considered the main focus
of nephrologists in the past. However, the relative importance
of these CKD-associated mineral disturbances has been
increasingly acknowledged and greatly associated with
progression of renal failure, cardiovascular (CV) events,
and mortality. Among all these mineral disturbances, the
activation of vitamin D receptors (VDRs) seems to have
independent beneficial pleiotropic extraskeletal effects.4,5
CHRONIC KIDNEY DISEASE–MINERAL AND BONE DISORDER
Multifactorial hypocalcemia, calcitriol and vitamin D defi-
ciency, P retention and fibroblast growth factor (FGF)-23
dysregulation, resistance to the action of PTH and vitamin D,
and decreased activation, decreased number, or downregula-
tion of several related receptors (VDR, Ca-sensing receptor,
FGF-23/Klotho), among other factors, can lead to prolonged
and excessive synthesis and secretion of PTH, eventually
leading to the development of SHPT and different forms
of renal osteodystrophy.1,6,7 Bone is currently considered an
active ‘endocrine’ organ, as demonstrated by the osteocyte
product FGF-23 regulating P balance, vitamin D metabolism,
and PTH production.8,9 Furthermore, the effect of PTH
on FGF-23 has been recently described, completing a
bone–parathyroid endocrine feedback loop in which SHPT
has been shown to be essential for the high FGF-23 levels in
early CKD.10 The role of FGF-23 and Klotho in CKD is
widely covered by Vervloet and Larsson in this issue.11
Beyond parathyroid and bone diseases, numerous studies
have shown clearly the association between disorders of
mineral metabolism (and the therapies used to correct these
abnormalities) and fractures, extraskeletal and vascular
calcification (VC), progression of renal failure, CV disease,
and mortality.12,13 These studies have prompted the
development of the new term CKD–mineral and bone
rev iew http://www.kidney-international.org
& 2011 International Society of Nephrology
Correspondence: Jordi Bover, Department of Nephrology, C. Cartagena
340-350, 08025, Barcelona, Spain. E-mail: jbover@fundacio-puigvert.es
122 Kidney International Supplements (2011) 1, 122–129
disorder (MBD) to acknowledge its systemic consequences
and damage to organs beyond bone, primarily VC. Thus,
CKD–MBD is a real syndrome, currently defined by one or a
combination of the following: (1) abnormalities of Ca, P,
PTH, or vitamin D metabolism; (2) abnormalities in bone
turnover, mineralization, volume, linear growth, or strength;
and/or (3) vascular or other soft-tissue calcifications12–14
(Figure 1).
RENAL OSTEODYSTROPHIES AND VITAMIN D
Renal osteodystrophy
The old general term of renal osteodystrophy is currently
restricted to an alteration of bone morphology in patients
with CKD, representing one measure of the skeletal
component of CKD–MBD that is quantifiable by histomor-
phometry of bone biopsy.12,13 Although bone biopsy is
invasive and thus cannot be performed easily, it is the
gold standard for the diagnosis of renal osteodystrophy, as
biochemical parameters do not adequately predict the
underlying bone histology.13 This is a field with a particular
need for improvement, especially taking into account the
great variability of PTH assays15,16 and the current scarcity of
information available on bone behavior and bone disease
beyond the so-called intact PTH ‘extremes of risk’.13 Thus, a
significant proportion of patients with intermediate PTH
levels (that is, two to nine times the upper limit of normality
for a particular assay) present quite different rates of bone
formation, from adynamic bone disease (ABD) to normality
and hyperparathyroid bone disease.17,18
It is well known that the traditional types of renal
osteodystrophy have been defined on the basis of
turnover and mineralization, with substantial differences in
pathophysiology and treatment. A recent Kidney Disease:
Improving Global Outcomes (KDIGO) report has suggested
that bone biopsies in patients with CKD should be
characterized by determining bone turnover (T), mineraliza-
tion (M), and volume (V) (the TMV system). Six types of
bone disorder are distinguished in the CKD–MBD complex:12
hyperparathyroid bone disease (high turnover, normal
mineralization, and any bone volume); mixed bone disease
(high turnover with mineralization defect and normal bone
volume); osteomalacia (low turnover with abnormal miner-
alization and low-to-medium bone volume); ABD (low
turnover with normal mineralization and low or normal
bone volume); and two distinct disorders due to specific
causative agents, namely, amyloid bone disease and alumi-
num bone disease.12,17
According to old studies, bone abnormalities are found
almost universally in patients with CKD requiring dialysis
(stage 5D) and in the majority of patients with CKD stages
3–5.1,18–23 Moreover, the distribution of histological types in
patients with CKD stage 5 has been changing over the
years.13,24 ABD is increasing in prevalence and in many
CKD populations now represents the most frequent type of
bone lesion.18,25,26 Steadily growing proportions of elderly,
diabetic, and malnourished patients may, at least partially,
explain this finding.
The unsolved problem of ABD
The term ‘aplastic’ or ‘adynamic’ bone disease was introduced
in the early 1980s. This type of disorder is characterized by a
low bone turnover with normal mineralization represented
by an absence of osteoid accumulation. In adynamic bone,
the number of osteoblasts, the bone formation rate, and the
activation frequency are markedly diminished. Bone histo-
morphometry cutoff levels in different studies are incon-
sistent, and the reported prevalence of ABD varies from
5 to 49% in CKD stages 3–4 (refs. 17, 21, 27–29) and from
10 to 71% in CKD stage 5D.17,18,21,27,29,30 The regulation
of osteoblast apoptosis is now recognized to be a major
mechanism in determining rates of bone formation.29
Increased osteoblast apoptosis and decreased osteoblasto-
genesis are important determinants of decreased bone
formation rate and activation frequency. A variant of ABD
(so-called ABD-V), characterized by high osteoclastic resorp-
tion, has also been described.31
In the past, aluminum overload was the predominant
cause of low-turnover bone disease in dialysis patients.
A chronic low-dose exposure with concomitant high doses of
vitamin D—probably favoring mineralization—was said to
preferentially lead to ABD rather than osteomalacia.32 Thus,
it is important to distinguish between aluminum-induced
and non-aluminum-induced forms of ABD.17,21,28,29 Several
other conditions decrease bone turnover and bone remodel-
ing activity. Independently of CKD, advanced age and
diabetes (through elevated levels of advanced glycation
end-products), glucocorticoid-induced osteoporosis, and
hypoparathyroidism are associated with low bone turnover.
Growth hormone resistance or insulin-like growth factor-I
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Figure 1 | The interrelated nature of biochemical abnormalities,
bone disease, and extraskeletal calcification in chronic
kidney disease–mineral and bone disorder. Reprinted from
Moe et al.,14 copyright 2011, with permission from Elsevier.
CVD, cardiovascular disease.
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insufficiency, excess of proinflammatory cytokines, and low
serum calcitriol levels likely have a role in suppressing bone
formation by inhibiting the number of osteoblasts that can
form bone.29 Low PTH levels or bone resistance to the action
of PTH in CKD (relative hypoparathyroidism) are also
regarded as important risk factors for ABD,1,17,21,26,29,33 and
many factors from P loading, decreased calcitriol, or uremia
itself to antagonistic PTH fragments, downregulation of PTH
receptors, or decreased pulsatility of PTH have been related
to skeletal or calcemic resistance to PTH.2,34–37 Recently, the
bone formation rate has also been shown to be associated
with resistance to PTH.38 Several other factors have been
linked to ABD, such as Ca loading (via P binders or Ca in the
dialysate), vitamin D treatment (children with high doses,
high dialysate Ca content, or high incidences of hypercalce-
mia), peritoneal dialysis (dialysate Ca, increased glucose,
low albumin), acidosis, hypogonadism, inflammation, or the
use of bisphosphonates in CKD patients.17,21,29,39
The importance of ABD is that it diminishes the ability
to repair microdamage, resulting in an increased fracture
risk, according to observational evidence using bone markers
but not bone biopsies.40,41 Curiously enough, patients with
idiopathic hypoparathyroidism have preserved or increased
bone mass during therapy with Ca and vitamin D, and
patients with total parathyroidectomy do not have an
associated increase in the risk of fracture.29 Low PTH is also
associated with low protein intake and may be a risk factor
for malnutrition.29 As will be mentioned later, of more
importance is the existence of a relationship between ABD,
abnormal Ca balance, calcific arteriolopathy, and VC,29 and
the fact that a U-shaped curve depicts PTH levels and
mortality.42 Thus, the causal relationship between ABD and
vascular disease may, at least in part, explain why not only
high but also low intact PTH plasma levels, as well as low
PTH and high serum Ca levels (a combination typical
for ABD), are associated with increased mortality.42–44 This
finding is not, however, uniform across studies.45
VDR activation is essential for bone formation
Multiple circulating factors contribute to bone activity by
interfering with PTH receptor, FGF-23/Klotho, or VDR
pathways. Deficiency in vitamin D and its metabolites
leads to a failure in bone formation primarily caused by
dysfunctional mineralization. It is also well known that
vitamin D not only indirectly decreases bone formation rate
in hyperparathyroid bone disease, but also directly increases
both bone turnover and bone growth.36,46 Recent studies in
VDR-knockout mice have identified the VDR as being crucial
in maintaining normal bone formation and bone miner-
alization by directly enhancing osteoblast differentiation.47,48
In this model, Ca and vitamin D had both independent and
interdependent effects on skeletal and mineral homeostasis.
Mineralization of bone reflected ambient Ca levels rather
than the calcitriol/VDR system, whereas increased Ca absorp-
tion and optimal osteoblastogenesis and osteoclastogenesis
were modulated by calcitriol/VDR.
VDR activation of the osteoblast also functions to prevent
apoptosis, similarly to the effect of estrogen and androgen
receptors in preventing apoptosis of osteoblasts and osteo-
cytes. Intermittent injections of PTH also serve an anti-
apoptotic function to increase bone formation and bone
mass in contrast to continuous PTH infusions, which cause
bone loss.49,50 In addition, osteoblasts contain 1a-hydro-
xylase, presumably to function in an autocrine/paracrine
manner to maintain bone formation. It is necessary to
remember that vitamin D upregulates its own receptor,
whereas PTH decreases VDR and blocks homologous
upregulation.29,51 As expected, it has been demonstrated that
the actions of VDR activators on bone are more important
than those expected just for the inhibition of PTH, and thus
the effects of active vitamin D compounds and calcimimetics
on bone differ under certain experimental conditions in
vivo.52 Moreover, some of the improvement in Ca and
skeletal homeostasis seen in VDR-knockout mice may
occur through alternative vitamin D signaling pathways.53
Interestingly, other actions of vitamin D are explained by
mitochondrial non-genomic activity of VDR,54 making way
for challenging future studies on VDR physiology.
Different VDR activators may also differentially affect
bone. In an in vitro study, Nakane et al.55 found that
paricalcitol caused less Ca release from mouse calvariae than
did calcitriol and doxercalciferol; furthermore, paricalcitol
was the most effective preparation in stimulating collagen
synthesis. The authors concluded that this bone effect
of paricalcitol may contribute to its lower calcemic profile
and that paricalcitol may be more effective in stimulating
bone formation. Importantly, opposite effects of calcitriol
and paricalcitol on the PTH ratio (whole PTH(1–84)/
carboxy-terminal PTH) have been described in patients with
CKD stage 5D.56 The relatively higher PTH 1–84 levels with
paricalcitol is in agreement with data obtained in a rat model
of renal failure showing that paricalcitol can prevent and treat
SHPTwithout a major decrease in bone turnover.57 There are
no data on the effects of new activators of the VDR on
human bone.
Finally, with regard to renal osteodystrophy, it is necessary
to consider that an early diagnosis of CKD, through
the generalized use of estimated glomerular filtration rate
laboratory reports, will allow earlier diagnosis of biochemical
SHPT, abnormalities in vitamin D metabolism, and
CKD–MBD.58–60 Efforts should be made to improve our
knowledge of bone histology and its relationship with new
biochemical parameters. Earlier reports suggesting that the
use of the PTH ratio improves the prediction of bone
histology56,61 have not been corroborated in subsequent
studies. Bone alkaline phosphatase as well as new parameters
may improve the predictive value of intact PTH or the PTH
ratio.62,63 It is also of particular importance to learn the effect
of different treatments on bone outcomes, particularly the
normalization of bone histomorphometry (as stated in the
recent KDIGO Clinical Practice Guidelines) and bone
buffering capacity, as it is becoming increasingly clear that
124 Kidney International Supplements (2011) 1, 122–129
rev iew J Bover and M Cozzolino: Vitamin D receptor activation in CKD–MBD
there is a link between abnormal vascular processes (that is,
VC) and bone metabolism (the so-called bone–vascular axis),
and this may also have an impact on survival.8,13,64,65
VC, BONE ACTIVITY, AND VDR ACTIVATION
VC is a common feature in both prevalent and incident
dialysis patients, as well as before entering dialysis.66–68 VC
has been classically associated with both atheromatosis and
atherosclerosis, as well as poor outcomes.69,70 Uremia is a
calcifying environment and CKD has been described as the
‘perfect storm’ for CV calcification.71 The presence of VC in
patients with CKD is multifactorial, and several biochemical
abnormalities (excessive P loading, hyperphosphatemia,
hypercalcemia, high Ca P product, FGF-23, and high and
low PTH levels) have been related to clinically significant VC.
This topic is widely reviewed by Brandenburg et al. in this
issue.72
It is not clear which aspect of bone pathology is most
closely associated with VC. Not only severe forms of SHPT
but also low levels of PTH are associated with VC. As
mentioned previously, low PTH levels seem to increase the
prevalence of both ABD and VC,17,21,69,73 likely by preventing
the Ca-buffering ability of bone and the handling of any
extra-Ca load.74,75 Using bone biopsies, Tomiyama et al.76
found an association of VC with bone density, volume, and
formation rate in CKD patients who are not yet in dialysis
treatment. Similarly, London et al.73 found an association
between VC and indices of low bone turnover in the aorta
and systemic arteries of dialysis patients. In an expanded
cohort, London et al.69 reported a significant interaction
between the dose of Ca-containing P binders, bone activity,
VC, and stiffening. Of relevance was the fact that Ca load had
a significant impact on VC and stiffness in patients with ABD
when compared with patients with active bone. On the other
hand, Barreto et al.77 did not observe an association between
the type of bone disease and coronary calcification on cross-
sectional analysis. In a prospective study, the same authors
found a negative correlation between coronary calcifications
and trabecular bone volume, and low-turnover bone status at
the 12-month bone biopsy was the only independent
predictor for progression of coronary artery calcification.78
Adragao et al.79 completed these results by describing an
association between low bone volume, but not bone turnover,
and coronary calcifications. This effect was not observed in
patients who were on dialysis for more than 6 years. Finally,
Asci et al.30 recently reported that bone formation rate is
positively correlated with calcification scores as well as lower
bone volume. When only patients with coronary calcifica-
tions were included, there was a U-shaped relationship
between coronary calcifications and bone turnover, whereas
the association with bone volume was lost.30 The discrepan-
cies among these different studies may be due to the different
vascular zones analyzed, different aluminum exposures in
the past, number of parathyroidectomized patients, dialysis
vintage, age, gender, diabetes, or other factors. Adragao
et al.80,81 have also shown that femoral bone density reflects
histologically determined cortical bone volume, as well as
associations between measurement of bone mineral density
and VC or arterial stiffness. In any case, bone is currently
considered an important variable when evaluating predis-
posing factors for VC. Frequent associations of osteoporosis
and atherosclerotic VC or CV disease have also been observed
in postmenopausal women,82 as have associations between
the progression of VC and bone demineralization, under-
lining the importance of this relationship beyond CKD.
Other multiple risk factors, passive and active regulated
processes, have also been associated with the occurrence and/
or progression of VC and, as mentioned before, they are
comprehensively reviewed elsewhere in this Supplement.
It is important to emphasize that different vitamin D
derivatives functioning on the same VDR (selective VDR
activators such as paricalcitol or maxacalcitol) seem to have
different effects on Ca and P intestinal absorption at the
same degree of PTH suppression.83–85 Thus, the affinity of
paricalcitol for the VDR is three times less than that of
calcitriol, but its calcemic and phosphatemic effects have
been shown to be 10 times lower.86 The affinity of paricalcitol
for vitamin D-binding protein is also three times less than
that of calcitriol. Beyond the effect on Ca and P levels,
selective VDR activators have uniformly shown distinct
independent effects on VC. For instance, paricalcitol or
maxacalcitol appear to have fewer in vivo experimental CVor
renal procalcifying effects than doxercalciferol or equivalent
doses of calcitriol despite comparable serum Ca P pro-
ducts.87–90 Whether the described differential effects on bone,
such as relatively lower bone suppression, contribute to this
observation is not known.55 Considering all the previous
observations on biochemical parameters and the striking
distinct effects on VC, compounds that selectively activate
VDR might enhance CV and renal protection,91–93 providing
a significant clinical benefit due to the known relationship
between Ca and P levels and VC and mortality.45,66,67
VDR ACTIVATION AND VASCULAR DYSFUNCTION
The key discoveries regarding the conversion of vitamin D to
its hormonal form and its regulation, as well as the evolving
picture of its molecular mechanisms of action, have been
described elsewhere.5,85 Nevertheless, the recognition of its
role beyond regulation of Ca homeostasis and bone
metabolism represents a recent development. Vitamin D
deficiency is an increasingly recognized public health
problem in the general population and in chronic diseases
such as CKD.5 Impaired VDR activation and signaling results
in cellular dysfunction in several organs and biological
systems, leading to an increased risk for disturbances of
immunity, cancer, cell differentiation, infection, diabetes,
and, in CKD, for arteriosclerosis, arterial dysfunction, and
VC.4,5,94 The relationship between vitamin D deficiency and
heart disease has been extensively reviewed by Pilz et al. in
this issue.95
VDR is ubiquitous and both VDR and 1a-hydroxylase
(CYP27B1) are present in the CV system.94 The action of
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vitamin D in these tissues is implicated in the regulation of
endothelial, VSMC, heart function, inflammatory, and
fibrotic pathways and immune responses. Failure of CV
VDR activation is associated with many CV problems, as well
as the progression of kidney and CV disease.4,5,94,95
In view of the foregoing, it seems likely that the
relationship between VDR activation and hard outcomes,
both in CKD and the general population, extends at least
partially beyond VC and bone activity, as discussed
previously. Furthermore, recent epidemiological evidence
suggests that there is a narrow range of vitamin D levels at
which vascular function is optimized.96 Levels above or below
this range seem to confer a significant increase in risk for CV
disease,96 and thus a U-shaped curve or a reversed J curve
may describe quite well the relationship between adverse
systemic or vascular effects and the vitamin D status.97 In
Figure 2, we depict the relationship between reduced VDR
activation and outcomes. In addition to Pilz et al. in this
issue,95 the narrow relationship of the heart, CV system, and
kidney with the vitamin D system has recently been
reviewed.94 In both dialysis and non-dialysis patients, vitamin
D deficiency affects survival, and activation of VDR is
associated with improved survival.98–101 This observation may
not be surprising, considering that SHPT is associated with
higher mortality even in moderate non-dialysis CKD.102
Nevertheless, these survival benefits are observed even beyond
mineral metabolism control as they are significant over a
wide range of biochemical mineral metabolism parameters
(that is, higher and lower quartiles of Ca, P, and PTH serum
levels), VC scores, and measures of stiffness.103 Thus,
pleiotropic effects of vitamin D likely have a role.
In dialysis patients, a huge retrospective study suggested
that intravenous paricalcitol may provide additional survival
benefits as compared with intravenous calcitriol;104 however,
although consistency in the beneficial effects of vitamin D in
CKD patients is important, differences among the specific
vitamin D compounds are still a matter of controversy.105
It also has to be admitted that the overall exposure to vitamin
D over time may be higher with selective VDR activators, as
intermittent drug withdrawal due to hypercalcemia or
hyperphosphatemia is less frequent owing to their wider
therapeutic window.4 As therapy with VDR activators
appears to be useful in preventing bone loss and in decreasing
morbidity and mortality, across different biochemical
mineral metabolism parameters, some consider vitamin D
and/or selective VDR activation to be essential therapy in
CKD regardless of bone turnover status.29,106 It is conceivable
that other beneficial effects of activation of the VDR beyond
bone result in some benefit even in the presence of ABD.17
However, the current Kidney Disease Outcomes Quality
Initiative and KDIGO recommendations limit the adminis-
tration of VDR activators for the treatment of hyper-
parathyroidism only.107 Moreover, if vitamin D therapy
is planned in patients with CKD for reasons beyond
CKD–MBD, such as reduction of albuminuria in patients
with type 2 diabetes mellitus,108 only a selective VDR
activator has shown this ability in a recent prospective
short-term study. In this setting, selectivity is probably
desirable considering the long-term potential consequences,
such as the impact on Ca levels, the development of ABD, or
the potential effects on VC of different VDR activators.
In conclusion, VDR can be activated by vitamin D or
selective VDR activators. Selective VDR activation is defined by
different effects at the tissue and molecular (gene) levels.
A selective effect of paricalcitol in mineral metabolism is
identified by its low calcemic, low phosphatemic profile. On
the basis of gene expression profiles, there are other non-
mineral metabolism effects and tissue-specific differences
between vitamin D and selective VDR activation. Thus, treating
individual components of CKD–MBD is no longer recom-
mended, and a wider perspective encompassing skeletal, renal,
and CV effects is required. In this regard, selective VDR
activation has been associated with survival improvement at
least in dialysis patients, and new VDR activators should be
considered a novel and interesting approach to enhance the
standard of care in these high-risk patients.
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